• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by BeyondSpring Inc.

    8/29/24 4:30:20 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BYSI alert in real time by email
    bysi20240208_6k.htm
    Q2 2024 --12-31 false 0001677940 00016779402024-01-012024-06-30 iso4217:USD 00016779402023-01-012023-06-30 xbrli:shares iso4217:USDxbrli:shares 00016779402024-06-30 00016779402023-12-31 thunderdome:item
     

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of August 2024

     

    Commission File Number: 001-38024

     

    BeyondSpring Inc.

     

    BeyondSpring Inc.
    100 Campus Drive, West Side, 4th Floor, Suite 410
    Florham Park, New Jersey 07932
    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

     

     

     

    On August 29, 2024, BeyondSpring Inc. (the “Company”) reported financial results for the six months ended June 30, 2024.

     

    This Report on Form 6-K is incorporated by reference into the Registration Statement on Form F-3, File No. 333-280153, and the Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082, of the Company.

     

     

     

     

     

     

     

     

     

     

     

     

     

    BEYONDSPRING INC.

     

    CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND JUNE 30, 2024

     

    (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)

     

       

    December 31, 2023

       

    June 30, 2024

     
       

    $

       

    $

     
               

    (Unaudited)

     

    Assets

                   

    Current assets:

                   

    Cash and cash equivalents

        7,809       8,397  

    Restricted Cash

        9,941       -  

    Short-term investments

        193       5,963  

    Advances to suppliers

        306       280  

    Prepaid expenses and other current assets

        170       279  

    Total current assets

        18,419       14,919  
                     

    Noncurrent assets:

                   

    Property and equipment, net

        1,628       1,487  

    Operating lease right-of-use assets

        4,397       4,050  

    Other noncurrent assets

        364       441  

    Total noncurrent assets

        6,389       5,978  
                     

    Total assets

        24,808       20,897  
                     

    Liabilities and equity

                   
                     

    Current liabilities:

                   

    Accounts payable

        1,407       2,119  

    Accrued expenses

        2,581       1,772  

    Current portion of operating lease liabilities

        631       656  

    Deferred revenue

        1,751       2,001  

    Other current liabilities

        1,588       1,639  

    Total current liabilities

        7,958       8,187  
                     

    Noncurrent liabilities:

                   

    Operating lease liabilities

        3,364       3,030  

    Deferred revenue

        33,242       32,343  

    Other noncurrent liabilities

        3,705       3,612  

    Total noncurrent liabilities

        40,311       38,985  
                     

    Total liabilities

        48,269       47,172  
                     

    Commitments and contingencies

               
                     

    Mezzanine equity

                   

    Contingently redeemable noncontrolling interests

        11,874       12,274  
                     

    Shareholder's deficit

                   

    Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 39,015,476 and 40,300,350 shares issued and outstanding as of December 31, 2023 and June 30, 2024, respectively)

        4       4  

    Additional paid-in capital

        368,599       372,117  

    Accumulated deficit

        (396,302 )     (403,564 )

    Accumulated other comprehensive income

        894       1,258  
                     

    Total BeyondSpring Inc.’s shareholders’ deficit

        (26,805 )     (30,185 )

    Noncontrolling interests

        (8,530 )     (8,364 )

    Total shareholders' deficit

        (35,335 )     (38,549 )
                     

    Total liabilities, mezzanine equity and shareholders' deficit

        24,808       20,897  

     

     

     

     

     

     

     

     

     

    BEYONDSPRING INC.

     

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

     

    COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2024

     

    (Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)

     

       

    Six months ended June 30,

     
       

    2023

       

    2024

     
       

    $

       

    $

     
                     

    Revenue

        875       1,000  
                     

    Operating expenses

                   

    Research and development

        (9,214 )     (4,149 )

    General and administrative

        (5,145 )     (4,273 )
                     

    Loss from operations

        (13,484 )     (7,422 )

    Foreign exchange loss, net

        (200 )     (83 )

    Interest income

        281       46  

    Other income, net

        133       82  
                     

    Loss before income tax

        (13,270 )     (7,377 )

    Income tax benefits

        9       -  
                     

    Net loss

        (13,261 )     (7,377 )

    Less: Net loss attributable to noncontrolling interests

        (541 )     (115 )

    Net loss attributable to BeyondSpring Inc.

        (12,720 )     (7,262 )
                     

    Net loss per share

                   

    Basic and diluted

        (0.33 )     (0.19 )
                     

    Weighted-average shares outstanding

                   

    Basic and diluted

        38,976,761       39,070,994  
                     

    Other comprehensive loss, net of tax of nil:

                   

    Foreign currency translation adjustment

        1,249       576  

    Unrealized holding loss

        (5 )     -  

    Comprehensive loss

        (12,017 )     (6,801 )

    Less: Comprehensive gain (loss) attributable to noncontrolling interests

        (84 )     97  

    Comprehensive loss attributable to BeyondSpring Inc.

        (11,933 )     (6,898 )

     

     

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

    BeyondSpring Inc.

         
         
     

    By:

    /s/ Lan Huang     

     

    Name: Lan Huang

     

    Title: Chairperson and Chief Executive Officer

     

    Date: August 29, 2024

     

     

     

     

     

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.

    Exhibit

       

    101.INS

    Inline XBRL Instance Document

    101.SCH

    Inline XBRL Taxonomy Extension Schema Document

    101.CAL

    Inline XBRL Taxonomy Extension Calculation Linkbase Document

    101.LAB

    Inline XBRL Taxonomy Extension Label Linkbase Document

    101.PRE

    Inline XBRL Taxonomy Extension Presentation Linkbase Document

    101.DEF

    Inline XBRL Taxonomy Extension Definition Linkbase Document

    104

    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

     

     

     

     

     

     

     
    Get the next $BYSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BYSI

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    More analyst ratings

    $BYSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BeyondSpring downgraded by Jefferies with a new price target

    Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously

    12/2/21 5:17:19 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring downgraded by B of A Securities with a new price target

    B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously

    12/2/21 4:49:29 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring downgraded by William Blair

    William Blair downgraded BeyondSpring from Outperform to Mkt Perform

    12/1/21 10:55:31 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Decheng Capital China Life Sciences Usd Fund Iii, L.P. sold $227,675 worth of Ordinary Shares (131,311 units at $1.73) (SEC Form 4)

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    10/20/25 8:00:02 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Decheng Capital China Life Sciences Usd Fund Iii, L.P. sold $259,164 worth of Ordinary Shares (153,816 units at $1.68) (SEC Form 4)

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    10/15/25 8:07:14 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Decheng Capital China Life Sciences Usd Fund Iii, L.P. sold $24,720 worth of Ordinary Shares (13,876 units at $1.78) (SEC Form 4)

    4 - BeyondSpring Inc. (0001677940) (Issuer)

    10/10/25 5:58:02 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    SEC Filings

    View All

    SEC Form 8-K filed by BeyondSpring Inc.

    8-K - BeyondSpring Inc. (0001677940) (Filer)

    12/15/25 4:30:28 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - BeyondSpring Inc. (0001677940) (Filer)

    11/21/25 4:30:30 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by BeyondSpring Inc.

    424B5 - BeyondSpring Inc. (0001677940) (Filer)

    11/17/25 4:30:39 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

    Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced results from the Asian subset (n=488) of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alone in second- or third-line EGFR wild-type non-small cell lung cancer (NSCLC). Dublin-3's global intent-to-treat (ITT) patient d

    12/12/25 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

    In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registrational trial. This study will evaluate Plinabulin + docetaxel vs. docetaxel in non-squamous EGFR wild-type NSCLC after progression on anti-PD-(L)1 and chemotherapy, and is intended to serve as

    12/11/25 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

    Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with MD Anderson collaborators showed DC maturation and M1 macrophage polarization via a Plinabulin specific GEF-H1 dependent mechanism in responding patients with Plinabulin, PD-1 inhibitor and radiation. SEED, co-founded by BeyondSpring with 38% equity share, successfully completed its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New

    11/12/25 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Leadership Updates

    Live Leadership Updates

    View All

    SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors

    NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (SEED), an innovative global biotech company focused on engineering "molecular glues" and harnessing its targeted protein degradation (TPD) platform to attack previously undruggable targets, has appointed eminent international lawyer Ko-Yung Tung to its Board of Directors. SEED is a subsidiary of BeyondSpring (NASDAQ:BYSI), a global clinical-stage biopharmaceutical company developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Mr. Tung has served as a director and strategic advisor to leading international corporations and advisory councils, including Eisai Co., Ltd., Hawa

    10/23/23 7:45:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors

    Former Director at Eli Lilly, HSBC and MastercardBrings Almost Five Decades of Experience in Finance, Strategy and Risk Governance NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics (the "Company"), a BeyondSpring (NASDAQ:BYSI) subsidiary and global research company focused on harnessing and engineering "molecular glues," a targeted protein degradation (TPD) platform to attack previously believed undruggable targets, today announced that it has appointed Jackson Tai to its Board of Directors. Mr. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (after 10 years), HSBC (after 7 years), and Mastercard (after 15 years). He brings almost 5

    6/20/23 8:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

    SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment of Richard John Daly ("Mr. Daly") as the President of CARsgen Therapeutics Corporation, a subsidiary of the Company in the United States. Mr. Daly will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC operation, busin

    1/17/22 8:50:00 AM ET
    $BYSI
    $CPRX
    $OPNT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $BYSI
    Financials

    Live finance-specific insights

    View All

    BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

    Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential to Resensitize Tumors Progressed on PD-1/PD-L1 Inhibitors in Metastatic NSCLCSEED Therapeutics Enters into Targeted Protein Degradation Research Collaboration with Eisai with potential payment to SEED of up to $1.5 Billion and Completes $24 Million First Close of Series A-3 FinancingSEED Therapeutics' Lead Oncology Asset RBM39 Degrader Granted Rare Pediatric Disease and Orphan Drug Designations by the FDA FLORHAM PARK, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI

    3/27/25 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

    FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D. (Piedmont Cancer Institute), Alberto Chiappori, M.D. (Moffitt Cancer Center), an

    5/3/24 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors

    New Clinical Data from MD Anderson Presented at the Society for Immunotherapy of Cancer's 38th Annual Meeting80% DCR (disease control rate) in non-radiated tumor with Durable Responses in Heavily Pretreated Patients in 6 different cancersFull data was presented at SITC's 38th Annual Meeting; The Company will host a call at 8:30 a.m. ET today. Dial in: 877-407-0792, conference title: Clinical Significance of Plinabulin SITC Presentation with PI Dr. Steven Lin from MD Anderson NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platfor

    11/7/23 7:00:00 AM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BYSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BeyondSpring Inc.

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    11/14/24 9:52:50 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    2/14/24 4:30:59 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by BeyondSpring Inc. (Amendment)

    SC 13G/A - BeyondSpring Inc. (0001677940) (Subject)

    4/7/23 5:02:43 PM ET
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care